

Regulus Therapeutics Inc.
Form 8-K
June 12, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 10, 2013

Regulus Therapeutics Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State of incorporation)

001-35670
(Commission

File No.)

26-4738379
(IRS Employer

Identification No.)

Edgar Filing: Regulus Therapeutics Inc. - Form 8-K

3545 John Hopkins Court

Suite 210

San Diego, CA

(Address of principal executive offices)

92121

(Zip Code)

Registrant's telephone number, including area code: (858) 202-6300

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07 Submission of Matters to a Vote of Security Holders.

The 2013 Annual Meeting of Stockholders (the Annual Meeting) of Regulus Therapeutics Inc. (the Company) was held on June 10, 2013. As of April 11, 2013, the record date for the Annual Meeting, 35,982,358 shares of common stock were issued and outstanding. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

Proposal 1. Election of Directors

The Company s stockholders elected the nine persons listed below as directors, each to serve until the Company s 2014 Annual Meeting of Stockholders and until their successors are duly elected and qualified. The final voting results were as follows:

| | Votes For | Votes Withheld | Broker Non-Votes |
|----------------------------------|------------------|-----------------------|-------------------------|
| David Baltimore, Ph.D. | 26,512,055 | 318,333 | 3,155,807 |
| Bruce L.A. Carter, Ph.D. | 26,795,809 | 34,579 | 3,155,807 |
| Mark G. Foletta | 26,791,804 | 38,584 | 3,155,807 |
| John Maraganore, Ph.D. | 25,623,333 | 1,207,055 | 3,155,807 |
| Stelios Papadopoulos, Ph.D. | 26,755,220 | 75,168 | 3,155,807 |
| B. Lynne Parshall, Esq. | 25,636,027 | 1,194,361 | 3,155,807 |
| William Rastetter, Ph.D. | 26,801,998 | 28,390 | 3,155,807 |
| Douglas Williams, Ph.D. | 26,513,544 | 316,844 | 3,155,807 |
| Kleanthis G. Xanthopoulos, Ph.D. | 26,631,714 | 198,674 | 3,155,807 |

Proposal 2. Ratification of the selection of Independent Registered Public Accounting Firm

The Company s stockholders ratified the selection by the Company s Audit Committee of the Board of Directors of Ernst & Young LLP as the Company s independent registered public accounting firm for the fiscal year ending December 31, 2013. The final voting results were as follows:

| Votes For | Votes Against | Abstentions | Broker Non-Votes |
|------------------|----------------------|--------------------|-------------------------|
| 29,927,235 | 58,443 | 517 | 0 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 12, 2013

Regulus Therapeutics Inc.

By: /s/ Garry E. Menzel
Garry E. Menzel, Ph.D.
Chief Operating Officer and Executive Vice President, Finance